DiaCarta Inc. Launches QClamp™ Somatic Mutation Real-Time PCR Tests for KRAS, NRAS, EGFR, BRAF, PIK3CA and More Without DNA Extractions

DiaCarta today announced it has launched its QClamp™ somatic mutation tests, highly sensitive and rapid tests for KRAS, NRAS, EGFR, BRAF, PIK3CA and more in 2 hours without DNA extraction.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

Hayward, California (PRWEB) October 28, 2013

DiaCarta is a new Translational Genomics and Molecular Diagnostics company located in the San Francisco Bay area and is pioneering novel molecular diagnostics technologies for detection of cancer biomarkers in human body fluids including saliva, blood and urine - so called 'Liquid Biopsy' in the field of Oncology, today announced it has launched its QClamp™ somatic mutation tests, highly sensitive and rapid tests for KRAS, NRAS, EGFR, BRAF, PIK3CA and more in 2 hours without DNA extraction.

QClamp™ is a revolutionary new way to screen for somatic mutations, which utilizes a sequence specific wild-type template xeno-nucleic acid "Clamp" (XNA) that suppresses PCR amplification of wild-type template DNA and allows selective PCR amplification of only mutant templates. This allows the detection of mutant DNA in the presence of a large excess of wild-type template from any type of sample including FFPE, needle biopsy, whole blood and urine. The tests take less than 2 hours from start to finish without DNA extraction using special Qzol direct PCR lysis buffer and can detect below 0.1% mutated DNA.

“Recent studies have demonstrated that DNA sequencing is one of the least sensitive methods for characterizing mutation with only 10-20% of mutated DNA detected,” said Dr. Michael Powell, CSO of DiaCarta. “It has become clear that most if not all tumors are polyclonal and heterogeneous. Consequently, tumor driver mutations may not be detectable using standard DNA sequencing methods. Our QClamp™ tests are super sensitive and rapid. You don’t need to invest hundreds of thousands of dollar for a fancy digital PCR or sequencing machine. Our tests can be run on all currently available real-time PCR machines and everything to perform the tests is included in the kits.” 

“We are very excited to launch this new product line to meet the unmet market,” said Dr. Aiguo Zhang, founder and CEO of DiaCarta. “We have received overwhelming responses from the field and our tests are the best in the market to address the issues with somatic mutation testing in oncology personalized diagnostics. We are in the process of CE Mark applications and expect to receive them by end of this year.”
 
About DiaCarta Inc.
DiaCarta, based in Hayward, Calif., is developing and commercializing in vitro diagnostics for a wide range of diseases based on branched DNA (bDNA) Signal Amplification technology and QClampTM, proprietary technology platforms for gene quantitation and somatic mutation tests. DiaCarta offers a suit of oncogene test and companion diagnostic development services including QuatniVirus® HPVE6/E7 mRNA for cervical cancer and QuantiVirus® HPV E6/E7 mRNA for head-neck cancer tests.

For more information, please contact:
DiaCarta INC
information(at)diacarta.(dot)com
510-314-8858
http://www.diacarta.com


Contact

Attachments

EGFR Mutation Test Technote


QClamp Product Technote: DNA Extraction v.s. No DNA Extraction


QClamp Technology and Product Brochure


KRAS and JAK2 Mutation Test Technote


Colorimetric and Chemiluminescence Mutation Assays